tiprankstipranks
Trending News
More News >
Jiutian Chemical Group Limited (SG:C8R)
SGX:C8R
Singapore Market

Jiutian Chemical Group Limited (C8R) AI Stock Analysis

Compare
8 Followers

Top Page

SG:C8R

Jiutian Chemical Group Limited

(SGX:C8R)

Select Model
Select Model
Select Model
Neutral 41 (OpenAI - 5.2)
Rating:41Neutral
Price Target:
S$0.02
▲(0.00% Upside)
Action:ReiteratedDate:03/11/26
The score is primarily weighed down by sharply deteriorated financial performance (heavy losses, negative gross profit, and negative operating/free cash flow in 2023–2025). Technicals also remain weak with the price below long-term moving averages and negative MACD. The balance sheet’s moderate and improving leverage is a partial stabilizer but not enough to offset the profitability and cash burn issues, and valuation support is limited due to losses and no dividend yield provided.
Positive Factors
Moderate, improving leverage
The company's debt-to-equity improving to ~0.28 indicates a moderate capital structure and lower financial leverage compared with prior years. This provides a stabilizing buffer versus creditors, reduces immediate refinancing pressure and gives management more time to execute turnaround actions over the coming months.
Proven profitable history (2020–2022)
Prior years of strong profitability and revenue growth show the underlying business can deliver positive margins and scale. That historical performance suggests the operational model and market position can support recovery if demand or cost structures normalize, offering a realistic path back to profitability.
Improving cash flow trend in 2025
Free cash flow becoming less negative in 2025 signals early traction in reducing cash burn, likely from tighter working capital or cost controls. If sustained, this trend lowers near-term liquidity needs, reduces reliance on external funding and increases the company's runway to implement structural fixes over the next few months.
Negative Factors
Severe revenue decline and negative gross profit
Material revenue declines combined with consecutive years of negative gross profit indicate the core business is structurally unprofitable at current volumes or pricing. This undermines operating leverage, necessitates fundamental business model changes or significant cost cuts to restore sustainable margins over the medium term.
Persistent negative operating and free cash flow
Sustained negative operating and free cash flow mean the company is consuming cash to fund operations, increasing liquidity and financing risk. Continued cash burn pressures credit lines and forces either asset sales, increased debt or equity issuance, each of which can materially alter capital structure and shareholder value long-term.
Large net loss and negative returns on equity
A large 2025 net loss and multi-year negative returns on equity erode the equity base and impair solvency metrics. Over several months this raises the probability of recapitalization, covenant breaches or restructuring, which could dilute existing shareholders and constrain strategic options.

Jiutian Chemical Group Limited (C8R) vs. iShares MSCI Singapore ETF (EWS)

Jiutian Chemical Group Limited Business Overview & Revenue Model

Company DescriptionJiutian Chemical Group Limited, an investment holding company, manufactures and sells chemical-based products in the People's Republic of China. The company offers dimethylformamide, which is used as a feedstock in the production of polyurethane, pharmaceutical, and agro chemical products, as well as an absorbing agent primarily in electronics, acrylic fibers, and pharmaceutical products; and methylamine, a chemical feedstock in the organic chemical industry used in various areas, such as agricultural chemicals, medicines, fuels, synthetic resins, and leather making, as well as in the production of the solvent used for chemical fibers, activating agents, and photography. It also provides sodium hydrosulfite, a crystalline powder for use in water treatment, gas purification, cleaning, and stripping, as well as in the industrial processing of textiles, leather, foods, polymers, photography, and others; industrial and consumable carbon dioxide for use in aerated beverages, tobacco, and preserving vegetables; Oxygen-18, an isotope of oxygen to produce fluorodeoxyglucose; deuterium depleted water to inhibit cancer growth; and industrial methanol. In addition, the company is involved in the sale of downstream products; and research and development of isotope technology. Jiutian Chemical Group Limited was founded in 1994 and is based in Singapore.
How the Company Makes Moneynull

Jiutian Chemical Group Limited Financial Statement Overview

Summary
Income statement and cash flow are the key drags: revenue fell materially in 2023–2025 and margins flipped from healthy (2020–2022) to deeply negative, including negative gross profit in the last three annual reports, with a large net loss in 2025. Operating and free cash flow also turned negative in 2023–2025. The main offset is a comparatively moderate balance sheet with improving leverage (debt-to-equity ~0.28 in 2025), but continued losses risk eroding equity over time.
Income Statement
12
Very Negative
Performance has deteriorated sharply after 2022. Revenue fell materially in 2023–2025, and profitability flipped from healthy positive margins in 2020–2022 to deeply negative margins in 2023–2025 (including negative gross profit in the last three annual reports), culminating in a large net loss in 2025. The only clear strength in the history provided is the strong profitability and growth profile seen in 2021–2022, but the recent trajectory is decisively unfavorable.
Balance Sheet
45
Neutral
Leverage looks moderate with debt below equity across the period (debt-to-equity improving to ~0.28 in 2025 from higher levels earlier), which is a stabilizing factor. However, recurring large losses have driven negative returns on equity in 2023–2025, raising risk that continued losses could erode the equity base over time despite the currently reasonable leverage.
Cash Flow
18
Very Negative
Cash generation weakened meaningfully: operating cash flow and free cash flow turned negative in 2023–2025 after being strongly positive in 2020–2022. While free cash flow improved versus 2023 and 2024 (less negative in 2025), the business is still consuming cash and operating cash flow remains negative, which increases funding and liquidity pressure if the trend persists.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue393.13M106.22M243.76M598.56M2.43B2.17B
Gross Profit-147.20M-106.22M-82.26M-260.18M708.41M675.62M
EBITDA-141.98M-96.04M-118.22M-321.76M696.61M517.79M
Net Income-162.31M-165.01M-147.80M-344.64M490.50M324.90M
Balance Sheet
Total Assets1.42B699.69M1.05B1.29B1.99B1.89B
Cash, Cash Equivalents and Short-Term Investments698.48M198.16M400.41M529.62M1.11B773.55M
Total Debt234.88M127.62M289.32M265.88M134.64M228.18M
Total Liabilities469.16M248.45M427.02M523.23M764.65M1.08B
Stockholders Equity948.17M451.24M618.04M765.84M1.22B816.21M
Cash Flow
Free Cash Flow-356.18M-155.06M-171.63M-511.23M424.05M633.54M
Operating Cash Flow-328.39M-129.87M-81.58M-385.65M434.01M655.81M
Investing Cash Flow-27.72M-24.57M-89.54M-125.70M-9.85M-27.68M
Financing Cash Flow-53.04M-160.50M32.87M-732.00K-95.52M-110.89M

Jiutian Chemical Group Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.02
Price Trends
50DMA
0.02
Negative
100DMA
0.02
Negative
200DMA
0.03
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
43.20
Neutral
STOCH
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:C8R, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.20 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:C8R.

Jiutian Chemical Group Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
52
Neutral
S$37.21M-1.77-19.55%0.92%-7.45%-480.22%
41
Neutral
S$41.76M-1.64-30.86%-2.43%52.80%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SG:C8R
Jiutian Chemical Group Limited
0.02
>-0.01
-19.23%
SG:C05
Chemical Industries Far East Ltd.
0.49
-0.02
-3.92%
SG:5DS
MegaChem Ltd.
0.43
0.04
11.84%
SG:A55
Asia Enterprises Holding Ltd.
0.15
0.02
20.00%
SG:BEI
LHT Holdings Ltd
1.11
0.18
19.35%
SG:Y8E
Samurai 2K Aerosol Ltd.
0.13
0.07
118.33%

Jiutian Chemical Group Limited Corporate Events

Jiutian Chemical Drops Synthetic Ammonia Investment Amid Tightening China Credit
Dec 29, 2025

Jiutian Chemical Group has mutually agreed with Anyang Chemical Industry Group to terminate its planned investment in a synthetic ammonia project and the lease of a urea production facility in China, after reassessing the project’s commercial viability amid tighter lending conditions and stricter collateral and repayment requirements across the Chinese banking sector. The company stated that key conditions precedent, particularly securing adequate bank financing, could not be met, but emphasized that it has incurred no material capital expenditure, faces no penalties or break fees from the termination, and does not expect any material adverse impact on its financial position for the 2025 financial year; it will continue to evaluate other strategic and investment opportunities aligned with its long-term objectives and shareholder interests.

The most recent analyst rating on (SG:C8R) stock is a Hold with a S$0.03 price target. To see the full list of analyst forecasts on Jiutian Chemical Group Limited stock, see the SG:C8R Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 11, 2026